Clinical evidence suggests that the age-associated progressive cognitive decline observed in patients with Alzheimer's disease is linked to the extent of tau pathology- specifically, the degree and nature of tau phosphorylation, as well as the accumulation of β-amyloid in senile plaques [60, 61]. The gene discussed is MAPT; the disease is Alzheimer disease.